shown that repeated injections of SP result in a decrease in the intensity of CBS, or desensitization.
The goals of the present study were (1) to determine whether desensitization also develops to the CBS behavior produced by EAAs in the spinal cord, (2) to characterize the role of interneurons in desensitization, and (3) to examine possible interactions between EAAs and SP. While injection of NMDA at 2 min intervals resulted in desensitization to its CBS behavioral effect, behavioral responses to repeated injections of KA or Quis increased in intensity, exhibiting sensitization. The NMDA antagonist DL-2-amino-5-phosphonovaleric acid failed to alter sensitization to either KA or Quis but inhibited behaviors produced by SP and NMDA, suggesting an NMDAmediated component in SP-induced behavior. Concanavalin A, which is reported to block desensitization to the electrophysiologic effect of Quis, blocked sensitization to the behavioral effects of both Quis and KA. Strychnine, bicuculline, and !&aminovaleric acid each inhibited desensitization to SP and NMDA, supporting the notion of recruitment of inhibitory transmitters in the attenuation of NMDA and SP activity. Pretreatment with capsaicin selectively inhibited the development of behavioral sensitization to KA, suggesting an involvement of small-diameter C-fibers in the enhancement of responsivity to KA. Consistent with this, pretreatment with SP selectively potentiated the CBS response to KA. The potentiation of KA effects by SP and dependence of KA behavioral sensitization on C-fiber activity suggest a possible mechanism by which EAAs and SP may be involved in the mediation of pain.
The undecapeptide substance P (SP) and the acidic amino acids, Glu and Asp are found in high concentrations in the dorsal horn of the spinal cord (Besson and Chaouch, 1987) , where they are believed to act as excitatory neurotransmitters (Schneider and Perl, 1988) . There are currently three major excitatory amino acid (EAA) receptor subtypes that have been classified based on the preferential activation ofthese receptors by the EAAagonists NMDA, kainate (KA), and quisqualate (Quis) (Evans et al., 1978 (Evans et al., ,1979 McLennan and Lodge, 1979; Foster and Fagg, 1984) . In the spinal cord, SP is thought to act as a primary afferent transmitter that is especially important in nociceptive transmission (Lembeck, 1953; Salt and Hill, 1983; Besson and Chaouch, 1987) . Intrathecal administration of SP to mice elicits a dose-dependent, caudally directed biting and scratching (CBS) behavior (Hylden and Wilcox, 198 1; Piercey et al., 198 1) that has been postulated to reflect aversive activity (Sakurada et al., 1988; Wilcox, 1988 ). This behavioral model has been widely used as a tool to investigate the pharmacological effects of excitatory compounds in the CNS, especially with respect to pain transmission. Using this paradigm, we have demonstrated that repeated intrathecal injections of SP result in a decreased intensity of CBS behavior with each subsequent injection, that is, desensitization (Larson, 1988) . Behavioral desensitization is a decrease in the response to an agonist and can be brought about by a variety of mechanisms. SP, for example, typically exhibits a rapid desensitization in several systems (Laufer et al., 1988) and is thought to result from decreased activity at neurokinin-1 receptors. The ability of SP to induce hyperalgesia in rats has also been found to exhibit desensitization (Moochhala and Sawynok, 1984) . Desensitization to the CBS behavioral effects of SP appears to result from the action of inhibitory metabolites that attenuate the response to SP rather than downregulation of neurokinin-1 receptors (Larson, 1988; Igwe et al., 1990a,b,c) .
Intrathecal administration of EAAs also elicits CBS behaviors Wilcox, 1986, 1987) . This is of special interest as Glu and Asp have been postulated to be involved in pain transmission, based on several lines of evidence: (1) Glu is colocalized with SP in primary afferent C-fibers (De Biasi and Rustioni, 1988) ; (2) injection of formalin into the hindpaw of rats evokes the release of Glu and Asp in the dorsal spinal cord (Skilling et al., 1988) ; (3) antagonists of EAAs inhibit nociception (Cahusac et al., 1984; Aanonsen and Wilcox, 1987) ; and (4) intrathecal injections of NMDA produce an apparent hyperalgesic effect (Aanonsen and Wilcox, 1987) . SP and EAAs also appear to interact in a reciprocal fashion in the spinal cord as SP causes the release of Glu and Asp from the dorsal horn of rats ) and KA in turn elicits the release of SP in the same system (Murray et al., 1990) . While the acute effects of EAAs and SP in the spinal cord have been extensively studied, their effects and interactions after tonic release or application have not been studied in the whole animal.
Electrophysiologically, responses to EAAs in invertebrates have been found to exhibit a profound use-dependent decrement in responsivity (Takeuchi and Takeuchi, 1964) . While it was initially thought that vertebrate neurons failed to develop desensitization (O'Brien and Fischbach, 1986) , the use of improved drug delivery systems showed that these EAA receptors do exhibit rapid desensitization. The decrease in NMDA receptor responsivity appears to be calcium dependent and requires several seconds (Mayer and Westbrook, 1985; Zorumski et al., 1989) . In contrast, desensitization to Quis and RS-(ramino-3-hydroxy-5-methyl-4-isoxazole-propionic acid HBr (AMPA), an agonist at the same receptor as Quis, occurs within milliseconds and recovers within hundreds of milliseconds (Trussell et al., 1988; Tang et al., 1989) . The response to IL4 exhibits little or no desensitization . While these studies demonstrate desensitization to specific EAA agonists, it is unclear what the consequences ofthis desensitization are in the intact animal with respect to specific physiologic effects. In light of the tendency of EAAs to desensitize, it is important to determine whether the tonic release of EAAs or SP, such as would occur during chronic pain, might influence the intensity of the response to a subsequent release of one of these neurotransmitters and thereby influence the perception of pain.
If EAAs play a role in the mediation of pain, and if changes in the sensitivity to EAAs occur in these pathways, these changes would provide natural regulatory (analgesic or hyperalgesic) effects. The purpose of the present investigation was to study the effect of prolonged exposure of the spinal cord to the EAA agonists NMDA, KA, and Quis to determine whether the behavioral effects produced by these compounds, like those of SP, are altered after repeated injections. We used the paradigm of monitoring EAA-and SP-induced CBS behaviors to detect changes in the sensitivity of the spinal cord to these compounds because of the ease in quantifying CBS behaviors in unanesthetized, intact mice. We then examined the effect of tonic exposure to one compound on the response to the other excitatory compounds to detect changes in their interaction in the spinal cord in viva. The potential role of intemeurons in the mediation ofbehavioral sensitization or desensitization was then examined using antagonists of NMDA, GABA, and glycine.
Materials and Methods

Animals.
Male Swiss-Webster mice (20-25 gm, Biolab, White Bear Lake, MN) were housed four per cage and allowed to acclimate for at least 24 hr prior to use in experiments. Mice were allowed free access to food and water. Animals were used strictly in accordance with the Guidelines of the University of Minnesota Animal Care and Use Committee and those prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council [DHEW Publication (NIH) 78-23, revised 19781.
Drug administration. All injections were made intrathecally in mice at approximately the L5-L6 intervertebral space using a 30-gauge 0.5-inch disposable needle and a 50-~1 Luer tip Hamilton syringe after the method of Hylden and Wilcox (1980) . A cannula constructed of a 30-gauge needle attached to PE-10 tubing was used for repeated intrathecal injections as described elsewhere (Larson and Beitz, 1988) . A volume of 5 ~1 was used for all intrathecal injections. SP was administered in 0.85% acidified saline, containing 0.01 N acetic acid (Hall and Stewart, 1986) . For repeated injections of SP, 10 ng (7.5 pmol) were delivered four times at 2 min intervals. For repeated injection of EAA agonists, 0.2 nmol of NMDA, 0.025 nmol of KA, and 0.3 nmol of Quis were administered in 0.85% normal saline at 2-min intervals. The doses of SP and EAA agonists were chosen to be equieffective based on their ability to elicit CBS behaviors that were of similar intensity and of sufficient magnitude to be either significantly inhibited or potentiated.
Experimental protocol. Immediately after insertion of the cannula, animals were placed in a large glass cylinder containing approximately 2 cm of bedding. One minute later, mice were injected via the cannula, and the total number of bites and scratches occurring over the subse- quent 2 min interval was recorded. Mice were reinjected every 2 min, and the behaviors were recorded for a series of four injections. Injection of saline or acidified saline in the same volume and time interval failed to elicit biting and scratching behavior and appeared to have no effect on the normal exploratory behavior of the mice. Drugs. Substance P (SP) was purchased from Peninsula Laboratories (Belmont, CA). N-methyl-D-aspartic acid, kainic acid, quisqualic acid, DL-2-amino-5-phosphonovaleric acid (APV), bicuculline, 5-aminovaleric acid hydrochloride (5-AVA), capsaicin, and strychnine were purchased from Sigma Chemical Company (St. Louis, MO). Concanavalin A (Con A) from jack bean Canavalia ensiformis, specific for a-D-man- nose > u-n-glucose > WD-GlcNAc, was purchased from Boehringer Mannheim (Indianapolis, IN).
Statistics. Statistical analysis of the results was performed using Student's t test for unpaired or paired samples with significance accepted at p < 0.05. The results of cross-desensitization and cross-sensitization are expressed graphically as the percentage of a control group, as indicated in Results, but evaluated statistically prior to data transformation.
Results Sensitization and desensitization. Responses to repeated intrathecal injections of 0.2 nmol of NMDA resulted in an inverted U-shaped curve over time, as shown in Figure 1A . The number of behaviors after the fourth injection of NMDA was significantly less than those resulting from the first injection of NMDA, suggesting desensitization. Injection of half that dose of NMDA (0.1 nmol) failed to produce a significantly different response in any of the four responses.
In contrast to NMDA, repeated intrathecal injections ofeither KA or Quis resulted in the development of a dramatic and readily reproducible sensitization to the behavioral effects of these EAAs (Fig. l&C' ). The intensity of responses typically increased two to three times the response to the first injection. To determine whether the increased behavioral response to either IL4 or Quis was the result of a simple accumulation of drug in the spinal area, KA or Quis was administered repeatedly at the same dose as used in Figure 1 , Band C, but was not reinjected until the behavioral response to each injection had terminated. The criterion used to determine that the effect of each injection had terminated was the observation of a 10 set period during which there were no CBS behaviors. As shown in Figure 2 , the intensity of each behavioral episode increased with each injection. In spite of the increase in the time interval between injections caused by the delay between behavioral episodes, the intensity of the response to each injection of KA or Quis still increased, again suggesting the development of sensitization to KA-and Quis-induced CBS behavior rather than a simple accumulation of drug in the spinal area. Four repeated injections of KA administered at 15min intervals still significantly increased the behavioral response of the last injection by 53% over that obtained in response to the first injection (data not shown).
It is possible that behavioral sensitization or desensitization to these excitatory compounds results from an action in the supraspinal area. To determine the likelihood of this, we examined the distribution of dye injected intrathecally. No dye was detected in the supraspinal area of mice 2 min after the last of four 2 ~1 volumes injected intrathecally at 2 min intervals. In contrast, 8 min after a bolus injection of 8 ~1 of dye, there was substantial staining of the brainstem area. When drugs were injected in four 2 ~1 volumes at 2 min intervals, which appeared to result in little or no distribution to the supraspinal area, behavioral sensitization to IL4 and Quis and desensitization to SP and NMDA were still produced, suggesting that the major anatomical site involved in the development of behavioral sensitization and desensitization is the spinal cord.
Recoveryfrom desensitization and sensitization. The recovery of the behavioral response from the desensitizing effect of repeated injections of NMDA was observed by 7 min after the last of a series of four injections of 0.2 nmol NMDA (Fig. 3A) . Recovery of the desensitization to SP-induced CBS behavior has also been shown to occur within 5-10 min (Larson, 1988) . Complete recovery from the sensitization to KA and Quis occurred by 7 min after the fourth injection of 25 pmol of KA and 17 min after the fourth injection of 0.3 nmol of Quis, as indicated by a behavioral response to a challenge injection that was equivalent to that in mice previously injected with saline only (Fig. 3B,C) . Recovery from the sensitizing effect of Quis was longer and was not accompanied by a transient decreased responsivity. It appears that neither the decreased response to repeated injections of NMDA nor the increased response to either KA or Quis resulted from spinal damage caused by the intrathecal injection per se as injections of vehicle prior to injection of the EAA did not alter the response to the EAA. Eficct ofAPK Pretreatment at 1 min with 1 nmol of APV, an NMDA antagonist, followed by coadministration of NMDA with 0.12 nmol of APV, significantly inhibited the intensity of NMDA-induced CBS behaviors produced by each of four repeated injections of NMDA (Fig. 4B) . APV had no effect on the intensity of CBS elicited by a similar series of four injections of KA or Quis (Fig. 4C,D) . While APV appears to be selective for NMDA, identical injections of APV with SP also markedly inhibited the CBS behavior produced by a series of three injections of SP (Fig. 4A) . The effect of APV on the fourth injection of SP is not shown as several of these mice exhibited seizures at that time in response to this treatment paradigm and were immediately killed. The effect of APV on the responses to both NMDA and SP appears to be a simple inhibition of the effect of these compounds rather than an effect on the development of desensitization as the response to the first injection is inhibited by APV to a similar degree as the behavioral response to the third and fourth injections. The inhibition of SP behavior by APV appears to require pretreatment with APV, as coadmininistration of SP plus 1 nmol of APV failed to alter the response to a single injection of SP, as previously described by Aanonsen and Wilcox (1986) .
E@ct ofcon A. When tested electrophysiologically, repeated exposure to Quis results in a dramatic desensitization that is prevented by the lectin Con A . To determine the relationship between the behavioral sensitization observed in the present studies and the previously reported desensitization to Quis, we examined the effect of Con A on the behavioral response to repeated injections of EAAs and SP. A dose of 300 pmol of Con A was injected intrathecally 1 min prior to the series of four injections of either SP, NMDA, KA, or Quis. At this dose, Con A completely blocked the development ofsensitization to KA and Quis in addition to an inhibitory effect on the magnitude of the first response to Quis (Fig. 5C,D) . The same dose of Con A had no effect on any of the four injections of NMDA and a small inhibitory effect on the magnitude of all reponses to SP (Fig. 5A,B) .
Efict of GABA, antagonism. Pretreatment with 10 pmol of the GABA, antagonist bicuculline, 1 min prior to injection of EAAs or SP, did not alter the intensity of CBS behavior produced by a single injection of SP or any of the EAAs. Bicuculline did, however, protect against the development ofdesensitization to the behavioral effects of both NMDA and SP, as shown in Figure 6 , A and B. In contrast, pretreatment with bicuculline failed to alter the development of sensitization to either KA or Quis (Fig. 6C,D) . Intrathecal injection ofthis relatively low dose of bicuculline alone failed to elicit CBS behaviors over the 9 min test period.
Efict of GABA, antagonism. Pretreatment with 2 nmol of S-AVA, a GABA, antagonist, 5 min prior to challenge with EAAs and SP did not alter the intensity of behavioral responses to a single injection of SP, NMDA, KA, or Quis (Fig. 7) . Similar to the response profile elicited by pretreatment with bicuculline, 5-AVA pretreatment selectively inhibited the development of desensitization to SP and NMDA (Fig. 7A,B) without affecting the development of sensitization to either KA or Quis (Fig.  7C,D) . No CBS behaviors were observed during the 13 min observation period following injection of 2 nmol of 5-AVA alone. Efict of glycine antagonism. Pretreatment with 0.3 nmol of strychnine 1 min prior to coadministration of an additional 75 pmol of strychnine with NMDA was found to be sufficient to reverse the inhibitory effects ofglycine on NMDA. While strychnine had no effect on the initial response to either SP or NMDA, the addition of strychnine to the injection protocol inhibited the development of desensitization to both NMDA as well as SP (Fig. 8A,B) . The addition of strychnine with KA or Quis had no effect on the development of sensitization to their behavioral responses (Fig. 8C,D) . The CBS behaviors resulting after the injection of strychnine alone were not significantly greater than the random grooming behaviors seen after injection of saline.
Effect of pretreatment with capsaicin. Pretreatment with 0.8 pg of capsaicin 24 hr prior to the the injection of SP or EAAs was found to inhibit dramatically the development of sensitization to repeated injections of KA compared to the response observed in vehicle-injected control mice pretreated with 5 ~1 of a mixture (v/v) of 50% saline and 50% dimethylsulfoxide (DMSO) (Fig. 9C) . Pretreatment of mice with capsaicin failed to alter the magnitude of behavioral responses to either SP or Quis (Fig. 9A,D) . While the response to a single injection of NMDA was not altered, behavioral desensitization to NMDA was slightly inhibited by pretreatment with capsaicin (Fig. 9B) . The dose of capsaicin was chosen based on its ability to produce analgesia in the hot plate and abdominal stretch assays (Larson, 1989) .
Cross-desensitization. To determine whether desensitization to either NMDA or SP resulted in cross-desensitization with other excitatory compounds, mice were pretreated with three injections of either NMDA, SP, or vehicle and then challenged . Protection against the development of sensitization to the CBS behavioral effects of KA and Quis by Con A. Groups of five mice were pretreated intrathecally with either saline or 300 pmol of Con A 1 min prior to repeated injection of excitatory compounds. Each point represents the mean number (-r-SE) of CBS behaviors produced during a 2 min interval after each compound. Asterisks represent significant differences between the Con A and control groups: ***, p < 0.001. A, SP-induced behaviors were inhibited by pretreatment with Con A. B, The response to NMDA was not altered by pretreatment with Con A. C and D, The development of sensitization to KA and to Quis was completely blocked by pretreatment with Con A. The response to a single injection of Quis was also inhibited, suggesting either inhibition of other meditators in the CBS behavior or a very rapid development of sensitization, perhaps within the first 2 min.
with NMDA, SP, KA, or Quis and the magnitude ofthe response Cross-sensitization. To determine whether pretreatment with to EAA or tachykinin was compared to vehicle-injected control either KA or Quis produced cross-sensitization, mice were premice as shown in Table 1 . These results indicate that pretreattreated with three injections of either of these compounds and ment with a series of three injections of either NMDA or SP then challenged with a fourth injection of NMDA, SP, KA, or cross-desensitized each other to the same degree. Pretreatment Quis, as shown in Table 1 . The magnitude of the final CBS with NMDA, however, failed to alter the intensity of CBS beresponse to this fourth injection was then compared to the effect haviors in response to either KA or Quis, suggesting that the of that compound after vehicle injections only. Following this mechanisms involved in NMDA-induced desensitization inprotocol, pretreatment with Quis was found to potentiate the volve different neuronal paths than those mediating the CBS KA-induced CBS behavior and pretreatment with KA enhanced responses produced by either KA or Quis. Pretreatment with the intensity of Quis-induced behaviors, indicating complete three injections of SP, however, potentiated the response to a cross-sensitization between the two EAAs. While pretreatment subsequent injection of KA but had no effect on the response with Quis enhanced the effect of KA, it had no effect on the . Protection against desensitization by 5-AVA, a GABA, antagonist. Groups of five mice were pretreated intrathecally with either saline or 2 nmol of 5-AVA 5 min prior to repeated injection of excitatory compounds. Each point represents the average number (*SE) of CBS behaviors produced during a 2 min interval after injection of each compound. Asterisks represent significant differences between the 5-AVA and control groups: ***, p < 0.001. A, Desensitization to SP was inhibited by 5-AVA during the third and fourth injections. B, Desensitization to NMDA was inhibited by 5-AVA. C, Responses to KA injection were not affected by 5-AVA. D, Quis-induced CBS behaviors also were not altered by 5-AVA. ment with KA, however, not only failed to potentiate the response to NMDA and SP but significantly inhibited the response produced by these two compounds. The inhibitory effect of pretreatment with KA on the response to NMDA was greater than that on the response to SP.
Discussion Several lines of investigation support the involvement of SP and
EAAs in the mediation of pain perception in the spinal cord.
Substance P and SP binding sites (Hokfelt et al., 1975; Mudge et al., 1979; Helke et al., 1986) as well as EAAs and EAA receptors (Duggan and Johnston, 1970; Greenmyre et al., 1984; Weinberg et al., 1987) have been localized in superficial laminae of the dorsal horn, an area thought to be important in nociception. Noxious stimulation causes release of SP (Takagi, 1984) as well as the release of Glu and Asp (Skilling et al., 1988) while intrathecal injection of either SP (Yashphal and Henry, 1983) or NMDA (Aanonsen and Wilcox, 1987) results in hyperalgesia. It has been postulated that primary and secondary hyperalgesia caused by exposure to noxious stimulation is mediated in part by changes in spinal cord or other higher-order neurons (Kenshalo et al., 1982; LaMotte, 1984) in addition to changes in the peripheral tissue. Release of EAAs from large-diameter primary afferent fibers has also been proposed to be important in the mediation of neuropathic pain disorders such as allodynia, causalgia, or neuralgias (Willer et al., 1978 (Willer et al., , 1983 Bennett and Xie, 1988; Campbell et al., 1988; Bennett et al., 1989) . Tonic changes in the sensitivity to SP and EAAs may play a role in primary or secondary hyperalgesia or in chronic pain. It is not known whether the intrathecal injection of these compounds, which produces CBS behavior in mice, is sufficient to elicit pain (Frenk et al., 1988) ; however, this model allows us to study changes in the activity of compounds thought to be involved in nociception. Based on our previous work showing produced during a 2 min interval after injection of each compound. Asterisks represent significant differences between the strychnine and control groups: *, p < 0.05; ***, p < 0.00 1. A, Desensitization to SP was inhibited by strychnine. B, Desensitization to NMDA was inhibited by strychnine. C, Responses to KA were not affected by strychnine. D, Quis-induced CBS behaviors also were not altered by strychnine.
a desensitization to the behavioral effects of SP, we hypothesized that the behavioral activity produced by repeated injections of EAAs in the spinal cord may also differ from that elicited by their single injection. Electrophysiological studies describe the tendency of EAA-mediated events to desensitize (Trussell et al., 1988; or sensitize (Kauer et al., 1988) . Our data reflect a change in the response to repeated injections of EAAs, resulting in a rapidly developing sensitization to the CBS behavioral effects of KA or Quis and desensitization to repeated injections of SP and NMDA. Prolongation of the dosing interval to allow complete dissipation of each behavioral effect did not interfere with the enhancement of CBS, suggesting that the enhanced response is not simply due to an accumulation of drug. The development of sensitization to KA and Quis, as opposed to desensitization to NMDA and SP, is significant as it clearly indicates that (1) not all EAA receptors elicit the same tonic activity, in spite of similar acute behavioral effects, and (2) there are unique modulatory systems for the tonic activities of these compounds in vivo. Not only was sensitization to KA and Quis distinct from desensitization to SP and NMDA, but, as illustrated in Table 1 , the tonic effect of each excitatory compound on the response to challenge with either SP, NMDA, KA, or Quis resulted in a unique profile. The phenomenon of behavioral sensitization to KA has several parallels to "windup" of class 2 neurons of the rat dorsal horn in response to repeated electrical stimulation of their receptive fields (Davies and Lodge, 1987) . Windup was only evoked by stimulus currents that were sufficient to evoke a C-fiber vol- ley. Stimulation with currents that evoked only A-fiber responses did not induce windup. The possibility that behavioral sensitization to KA is similarly mediated by the release of SP is consistent with capsaicin's ability to inhibit sensitization to KA and SP's ability to potentiate the behavioral response to KA. Our preliminary results show that KA is capable of evoking the release of SP in the rat spinal cord (Murray et al., 1990) . In light of the widely held belief that small-diameter C-fibers release SP while larger-diameter fibers would more likely release EAAs and not SP, it is reasonable to postulate that windup involves release of SP, which potentiates the response to endogenously released EAAs in a manner similar to that seen during behavioral sensitization to KA. It has been proposed that intemeuronal transmission is mediated by Asp (Stone and Burton, 1988) interacting with NMDA receptors (Watkins and Evans, 198 1) . To discern whether sensitization or desensitization is mediated by NMDA activity, we determined the effect of APV, an NMDA antagonist, on behavioral responses to each excitatory compound. We chose a dose of APV that significantly inhibited but did not block the response to NMDA to ensure that any effect of APV observed was not simply due to paralysis. The insensitivity of IL4 or Quis to APV indicates that the NMDA receptor is not involved in the generation of their acute behavioral effects or in the development of behavioral sensitization. We and others (Aanonsen and Wilcox, 1986) have not previously observed an inhibition of the SP when coadministered with APV. After testing several doses and pretreatment intervals, we found that coadministration of SP with 1 nmol of APV does not inhibit the response to a single injection of SP, but pretreat-ment with the same dose of APV inhibits the response to SP without altering the rate of development of desensitization, perhaps reflecting the time required for diffusion of the drug to its site of action. These data suggest a role for NMDA receptors in the response to SP and is consistent with our previous work showing that SP evokes the release of Glu and Asp in the spinal cord of the conscious, freely moving rat .
The complete inhibition of KA-and Quis-induced sensitization by Con A suggests a possible link between sensitization to the behavioral effects of KA and Quis in vivo and desensitization to Quis seen electrophysiologically . Con A appears to act with some degree of selectivity as NMDA-induced desensitization is not altered by Con A in either electrophysiologic or behavioral paradigms. While the lectin Con A interacts with many glycosylated membrane proteins, it is of interest that Con A inhibited Quis receptor desensitization electrophysiologically but completely blocked the development of sensitization to the behavioral effects of both Quis and KA.
Baclofen, a GABA, agonist, is capable of inhibiting CBS activity caused by EAAs in the mouse spinal cord (Aanonsen and Wilcox, 1989) , while intrathecal injection of muscimol, a GA-BA, agonist, inhibits SP-induced CBS behaviors (Hwang and Wilcox, 1989) . Behavioral desensitization to NMDA and SP appears to be mediated, at least in part, by GABA. Our data, showing protection against the development of desensitization by either bicuculline, a GABA, antagonist, or 5-AVA, a GABA, antagonist, suggest that activation of GABAergic neurons does play a role in decreasing the behavioral response to SP and NMDA. Inhibition of GABA, receptors by bicuculline also produces an enhanced response to non-noxious tactile stimulation (Yaksh, 1989) , suggesting a possible link between allodynia and an inability to desensitize to NMDA.
Electrophysiologically, NMDA receptors desensitize more slowly in the presence of a high concentration of glycine , which may contribute to the slow desensitization in the micromolar concentrations of glycine in the extracellular fluid (Skilling et al., 1988) compared to the nanomolar concentrations of glycine often used electrophysiologically . The protection by strychnine against behavioral desensitization to SP and NMDA in the present investigation further supports an involvement of glycine in this phenomenon. We have previously shown a strychnine-insensitive, glycineinduced enhancement of NMDA activity using this behavioral model (Larson and Beitz, 1988) . Inhibition of desensitization by strychnine could result from either a decrease in glycine's strychnine-sensitive inhibitory actions or an unmasking of glytine's ability to facilitate NMDA activity via the strychnineinsensitive glycine site. The dose of strychnine used in the present study was based on a dose that produced no CBS behavior when injected alone, had no effect on the intensity of behaviors elicited by a single injection of either SP or NMDA, yet was sufficient to convert the inhibitory effect of 50 clg of glycine on NMDA-induced behaviors to a potentiative effect, suggesting a complete inhibition of the inhibitory glycine receptors and an unmasking of the strychnine-insensitive glycine sites. Potentiation in CBS behaviors during desensitization would therefore likely result from an enhanced release of glycine.
There are a number of observations that support the hypothesis that separate KA and Quis receptors exist in our system (Homfeldt and Larson, 1989) as well as others (Foster and Fagg, 1984) . The present study is consistent with the theory that KA and Quis activate two separate receptors to elicit CBS behaviors. KA and Quis each exhibit different times of recovery from behavioral sensitization and interactions with SP. Pretreatment with KA, but not Quis, decreased responses to NMDA and SP, and pretreatment with SP in turn enhanced the behavioral response to KA but not Quis. While behavioral sensitization to KA appears to be due to a capsaicin-sensitive effect, the mechanism underlying behavioral sensitization to Quis is not clear.
Desensitization to the behavioral effects of SP is reversible by a relatively high dose of naloxone (Larson, 1988) , suggesting that endogenous opioid activity is, at least in part, responsible for the development of desensitization to SP. The phenomenon of desensitization to SP parallels its role as a nociceptive transmitter as SP has been shown to produce a naloxone-reversible analgesia. SP is metabolized in the spinal cord to N-terminal peptide fragments (Igwe et al., 1990a) that are capable of inhibiting the CBS response to SP (Sakurada et al., 1988; Igwe et al., 1990a) perhaps by a direct interaction with a @-FNA-insensitive subtype of p-opioid receptor (Krumins et al., 1989 (Krumins et al., , 1990 or via novel SP N-terminal receptors (Igwe et al., 1990b,c) .
Changes in the tonic activity of EAAs may be important in a variety of physiologic or pathologic situations such as seizures, excitotoxicity, ischemia, and anoxia. In studies using embryonic tissue cultures, KA-induced toxicity is proposed to result from a lack of desensitization to KA receptors (Vyklicky et al., 1986) . One might speculate that KA toxicity may be mediated by similar events that lead to the development of behavioral sensitization to KA or Quis.
In summary, the intensity of CBS behaviors produced by NMDA, KA, Quis, and SP in the mouse spinal cord changes after tonic exposure. Behavioral responses to SP and NMDA decrease while responses to KA and Quis dramatically increase. While NMDA receptor activation appears to be necessary for SP-induced behaviors, reflecting the release ofendogenous EAAs, enhanced NMDA activity does not account for sensitization to KA or Quis. The inhibition ofdesensitization to SP and NMDA by GABA and glycine antagonists supports the hypothesis that behavioral desensitization results from enhanced activity of inhibitory GABA, and possibly glycine, interneurons. Documentation that sensitization to KA and Quis develops in vivo and that SP selectively potentiates subsequent KA activity is important as EAAs have been proposed to play a role in chronic pain, neuromas, excitotoxicity, and seizures.
